Actively Recruiting
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Led by Chinese PLA General Hospital · Updated on 2023-04-27
10
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.
CONDITIONS
Official Title
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 14 years or older, any gender
- Newly diagnosed NK/T-cell lymphoma confirmed by pathology according to WHO 2016 criteria
- At least one measurable lesion: lymph node lesion > 1.5 cm or extranodal lesion > 1.0 cm in short axis
- ECOG performance score between 0 and 2
- Clinical stage III or IV lymphoma
- Normal major organ function including: WBC ≥ 3.5 x 10^9/L, platelets ≥ 75 x 10^9/L, hemoglobin ≥ 80 g/L
- Liver function: AST and ALT ≤ 3 times upper limit of normal; total bilirubin ≤ 2.0 mg/dL
- Kidney function: creatinine clearance ≥ 60 mL/min; liver or kidney impairment due to tumor compression allowed
- Normal fibrinogen at first treatment cycle
- Expected survival longer than 6 months
- Agree to use effective contraception
- Able to understand and sign informed consent
You will not qualify if you...
- Prior allogeneic hematopoietic cell transplantation
- Active autoimmune disease
- Primary central nervous system lymphoma
- Current infection requiring treatment (re-enrollment possible after infection is controlled)
- Known HIV infection
- Known allergy to study drug or its ingredients
- Other active cancers requiring treatment that may interfere with study
- Any other condition making participation unsuitable as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ChinaPLAGH
Beijing, Haidian, China, 100853
Actively Recruiting
Research Team
Y
Yu Zhao, Graduate
CONTACT
S
Sai Huang, Graduate
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here